Microbot Medical expands U.S. operations to prep for first in-human clinical study
24 Jan 2024
Radiation TherapyClinical Study
The clinical research associate (CRA) will join the Braintree Massachuesetts–based company‘s established clinical team in the U.S. The team is led by Dr. Juan Diaz-Cartelle, chief medical officer of Microbot Medical.
“Following the successful completion of our pivotal GLP pre-clinical trial, and as we are in the final stage of submitting our IDE, having an in-house CRA is a key piece for establishing the right infrastructure for clinical trial execution” said Diaz-Cartelle in a release.
Microbot Medical’s Liberty system aims to improve the use of surgical robotics in endovascular procedures. The system eliminates the need for large, cumbersome, and expensive capital equipment, according to the company. It can also reduce radiation exposure and physician strain.
In December 2023, Microbot Medical completed a pre-clinical study of its Liberty system. The pre-clinical study is a necessary step toward Microbot Medical’s IDE submission to the U.S. Food and Drug Administration (FDA). During the study, three interventional radiologists used LIBERTY to perform a total of 96 robotic navigations.
The radiologists used Liberty to examine and evaluate target vessels with surrounding tissue microscopically after subjecting them to procedures using a range of commercially available intravascular catheterization devices. All of these devices were controlled and manipulated with Microbot Medical’s system.
Liberty is a single-use endovascular system. No dedicated infrastructure is required to use the system. This can lower barriers to obtaining and using the system, making the technology available to more healthcare providers, claimed Microbot Medical.
Microbot Medical is collaborating with Corewell Health for a multi-phase project to enable telerobotics between remote centers. The agreement also includes the mutual evaluation of the Liberty system for remote procedures.
Corewell Health is a not-for-profit health system with more than 60,000 employees, including over 11,500 physicians and advanced practice providers, and more than 15,000 nurses. It said it provides care and services in 21 hospitals, over 300 outpatient locations, and several post-acute facilities.
Microbot Medical said it offers micro-robotic technologies to improve clinical outcomes for patients and increase accessibility through the natural and artificial lumens, or tubular structures, within the human body.
This article originally appeared on our WTWH Media sibling site The Robot Report.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Indications
-Targets
-Drugs
-Chat with Hiro
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.